Krsnaa Diagnostics share price, P/E, ROE & financials

On 6 Nov 2026, Krsnaa Diagnostics was priced at ₹475.00, or 15.9× trailing earnings, against an industry P/E of 52.8×, and the shares are 43% below their 52-week high. Its ROCE of 11% is the second-lowest among the 7 largest Diagnostics & Research peers, and sales and net profit grew 17% and 18% a year over 3 years. Its dividend yield is 0.4%, and debt is 0.55× equity. It is a small-cap company with a market cap of ₹1,618 Cr, ranked 9th of 18 Diagnostics & Research companies by market cap; the shares fell 38% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹479.00
Day high: ₹484.95
Day low: ₹470.00
Prev. close: ₹482.90
Volume: 54.1K

Health check

1 good · 1 fair · 4 to check

ReturnsBehind
−37.5% over a year, better than 0 of 7 peers.
Price tagCheaper
P/E 15.9 vs industry 52.8.
GrowthSteady
Sales +16.6%, profit +17.8% a year over 3 years.
ProfitabilityWeak
ROCE 10.5% vs peer median 19.1%.
Balance sheetStretched
Debt 0.55× equity, interest covered 5.0×, Piotroski 3 of 9.
Red flags1 to check
43% below its 52-week high.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Diagnostics & Research

17 listed peers. Screen the industry

Small cap

₹1,618 Cr, #9 of 18 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹841 Cr · profit ₹97 Cr

Market cap: ₹1,618 Cr; Small cap
P/E: 15.9; Industry 52.8
Price to book: 1.57; Peers 11.99
Dividend yield: 0.40%
ROE: 10.9%; Peers 17.7%
ROCE: 10.5%; Peers 19.1%
Debt to equity: 0.55; Debt ₹534 Cr
EPS (TTM): ₹29.93; Face value ₹5
OPM (TTM): 26.2%; Net margin 11.6%
Sales growth: +31.5%; Latest quarter vs a year ago
Profit growth: +2.7%; Latest quarter vs a year ago
Price to sales: 1.92; EV/EBITDA 7.3

Strengths

Quarterly sales up 31.5% on a year ago.
P/E of 15.9 against an industry P/E of 52.8.
Positive operating cash flow in each of the last 4 years.

Risks to check

43% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Krsnaa Diagnostics

Krsnaa Diagnostics Limited provides diagnostic services in India. It offers mammography, stress tests, dual-energy X-ray absorptiometry scans, bone mineral density tests, computed tomography scans, and magnetic resonance imaging services, as well as tele-radiology and tele-pathology services. The company was incorporated in 2010 and is based in Pune, India.

Headquarters: Pune
Employees: 3,296
Sector: Healthcare
ISIN: INE08LI01020
Website: krsnaadiagnostics.com

Price range

52 weeks

₹463.10₹838.00

Today

₹470.00₹484.95

Avg volume (3M): 1.3 L
1-year return: minus 37.5%
From 52-week high: minus 43.3%

Peers · Diagnostics & Research

Compare with peers Screen the whole industry

Company
SAILIFESai Life Sciences	1,785.10	plus 11.95%	37,929	101.5	15.22	18.1%	15.1%	28.7%	21.3%	226.8%	0.00%	plus 72.7%
LALPATHLABDr. Lal Path Labs	1,970.00	plus 0.16%	32,941	56.5	11.99	25.7%	22.6%	30.2%	11.1%	28.3%	1.02%	plus 24.7%
SYNGENESyngene International	417.30	plus 0.77%	16,772	90.3	3.46	8.3%	3.9%	25.7%	5.4%	−12.0%	0.30%	minus 36.0%
VIJAYAVijaya Diagnostic Centre	1,468.60	plus 2.15%	15,126	74.4	14.29	19.1%	21.2%	43.1%	21.0%	26.9%	0.14%	plus 40.2%
METROPOLISMetropolis Healthcare	568.75	minus 0.39%	11,803	52.8	7.17	15.7%	14.6%	21.7%	12.7%	10.0%	0.35%	plus 12.5%
THYROCAREThyrocare Technologies	493.10	plus 0.68%	7,848	55.0	14.75	33.8%	26.4%	32.2%	16.7%	36.2%	1.89%	plus 8.3%
VIMTALABSVimta Labs	496.45	minus 2.14%	2,219	27.9	4.52	21.0%	17.7%	34.7%	8.9%	17.2%	0.40%	minus 23.3%
KRSNAAKrsnaa Diagnostics	475.00	minus 1.64%	1,618	15.9	1.57	10.5%	10.9%	12.7%	16.6%	17.8%	0.40%	minus 37.5%
Median of 7 peers	–	0.68%	15,126	56.5	11.99	19.1%	17.7%	30.2%	12.7%	26.9%	0.35%	12.5%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
206	181	193	236	271
147	135	138	178	200
59.2	46.4	54.9	58	71.1
28.7%	25.6%	28.5%	24.6%	26.2%
4.2	3.7	31.5	7.2	6.2
8.2	7.8	12.1	14.8	15.5
23.6	22.7	22.6	28	29.1
31.6	19.7	51.7	22.4	32.8
24.1%	22.5%	19.3%	26.2%	25.0%
23.9	15.2	41.7	16.6	24.6
7.25	4.66	12.70	5.04	7.54

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +16.6%
Profit CAGR 3Y: +17.8%
EPS CAGR 3Y: +17.0%
ROE: 10.9%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
487	620	717	773
–	+27.2%	+15.7%	+7.8%
364	475	527	561
123	144	190	212
25.3%	23.3%	26.5%	27.4%
17.2	14.4	18	15.4
6.4	14.1	21.8	32.4
53.8	74.5	88.3	90.5
0.2	−0.1	4.6	25.9
80.2	70	103	130
22.6%	18.8%	24.4%	22.2%
62.1	56.8	77.6	101
–	minus 8.5%	+36.5%	+30.7%
19.29	17.31	23.56	30.88

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
15.7	16.1	16.1	16.2
723	794	867	964
32.5	160	204	534
139	202	195	309
910	1,172	1,282	1,824
503	691	686	952
34.9	46.2	18.8	301
156	15.1	129	78.1
109	175	68.4	361
108	244	379	132
910	1,172	1,282	1,824

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
76.3	24.3	87.3	143
−109	−129	−99.6	−396
−33.1	84.2	13.8	279
−65.7	−20.3	1.5	26.4
−141	−194	−127	−219
−65.1	−170	−39.3	−76.2
−7.8	−8.6	−8.1	−8.9

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 13.5% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you